Compare American International Group Inc (AIG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs Sana Biotechnology Inc — how do they compare? American International Group Inc trades at $76.37 (market cap $40.42B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: American International Group Inc is far larger — about 35.8× Sana Biotechnology Inc's market cap, and American International Group Inc pays a 2.59% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| AIG | SANA | |
|---|---|---|
Market Cap | $40.42B | $1.13B |
Sector | Financials | Health |
52-Week High | $86.59 | $5.92 |
52-Week Low | $71.89 | $2.68 |
Enterprise Value | $48.06B | $1.05B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $76.42, down 1.53% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with $2.11 EPS versus $1.89 expected, driven by robust underwriting income. Revenue for 2025 was $26.77B with net income of $3.10B, yielding an 11.12% net margin. The stock carries a P/E of 14.11 and a consensus analyst price target of $89.00, suggesting potential upside from current levels.
The outlook for AIG is mixed; solid earnings performance and a diversified insurance portfolio support growth, but competitive pricing pressure and investment income headwinds pose risks. With 39% of analysts rating it a Buy, the stock appears undervalued relative to its price target, though near-term catalysts may be limited amid broader market volatility.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
